A 69-year-old man with newly diagnosed prostate cancer PSA 274 ng/mL, Gleason 4+3, T-stage 3b) underwent 68Ga-PSMA PET/CT for staging with follow-up scans 6 and 13 weeks after androgen deprivation therapy (ADT) initiation. Six weeks after ADT initiation, lymph node metastases observed at staging showed metabolic and radiological regression, whereas the skeleton showed increased PSMA uptake in existing bone metastases and several new PSMA-avid lesions. Skeletal PSMA uptake decreased after 13 weeks of ADT, and prostate-specific antigen decreased to 16 ng/mL. These findings suggest the presence of the flare phenomenon to ADT in bone metastases seen on PSMA PET/CT.
From the Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital; and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Received for publication May 29, 2018; revision accepted July 28, 2018.
Conflicts of interest and sources of funding: H.D.Z. has received an unrestricted grant from Danielsen Foundation. L.J.P. has none to declared.
Correspondence to: Helle D. Zacho, MD, PhD, Department of Nuclear Medicine, Aalborg University Hospital, Hobrovej 18-22, Postboks 365, DK-9100 Aalborg, Denmark. E-mail: email@example.com.